Back to search
FDAFDA · Food and drugs·Recall number D-1498-2022

Difluprednate Ophthalmic Emulsion, 0.05%, 5 mL bottle, RX only, Manufactured for Exelan Pharmecuticals, Inc., Boca Raton, FL 33432, NDC 76282-708-50.

Published September 14, 2022 · Recall initiated: August 22, 2022

Summary

FDA records drug Class II recall D-1498-2022, published September 14, 2022 and initiated August 22, 2022. Recalling firm: CIPLA; Status: Terminated; Reported quantity: 3,468 bottles; Lot: Lot # DEG5BD2, Exp 07/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility: customer complaint for defective container where breakage of the protective cap exposes tip of eye drop which could compromise sterility.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
CIPLA
Distributor
Nationwide in the USA
Lot
Lot # DEG5BD2, Exp 07/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Difluprednate Ophthalmic Emulsion, 0.05%, 5 mL bottle, RX only, Manufactured for Exelan Pharmecuticals, Inc., Boca Raton, FL 33432, NDC 76282-708-50. recalled?

Yes. FDA published recall D-1498-2022 on September 14, 2022. Reported hazard: Lack of Assurance of Sterility: customer complaint for defective container where breakage of the protective cap exposes tip of eye drop which could compromise sterility.

What should I do if I have this product?

Voluntary: Firm initiated · Letter